人肺癌组织中caspase-3及其底物PARP蛋白的表达和意义  

Expression and Significances of Caspase-3 and its Substrates PARP Proteins in Human Lung Cancer

作　　者：陈洪雷[1] 高俊[2] 梁素美[1] 刁路明[1] 邹祖玉[1] 

机构地区：[1]武汉大学医学院病理学教研室,武汉430071 [2]荆门职业技术学院医学院,荆门448000

出　　处：《武汉大学学报（医学版）》2005年第6期726-729,F0003,共5页Medical Journal of Wuhan University

摘　　要：目的:检测caspase-3基因及其底物多聚ADP-核糖聚合酶(PARP)在人肺癌组织的表达及与临床病理特征的关系。方法:采用第2代免疫组化Elivision法和Western blot法检测57例人肺癌原发灶中caspase-3、PARP蛋白的表达。结论:通过Western blot和免疫组化检测caspase-3、PARP的蛋白表达结果一致,在57例肺癌原发灶中caspase-3、PARP 2种蛋白表达阳性率分别为:66.67%,33.33%。caspase-3与细胞分化程度(P=0.023)、淋巴结转移(P=0.004)和组织学类型显著相关(P=0.036),PARP与淋巴结转移显著相关(P=0.025)。57例人肺癌组织中,caspase-3的表达与PARP呈显著负相关(P=0.001)。结果:caspase-3通过降低其底物PARP的表达从而促进肿瘤细胞的凋亡,明显地抑制了肺癌的侵袭和转移。Objective： To investigate the relationship between the expressions of caspase-3 gene, and its substrates Poly ADP-ribose polymerase （PARP） and the clinicalpathological characteristic of pulmonary carcinoma. Methods： Caspase-3 and PARP protein levels in 57 patients with pulmonary carcinoma （21 patients with squamous cell carcinoma, 27 with adenocarcinoma, 4 with large cell carcinoma and 5 with small cell lung carcinoma） were detected by the second generation immunohistochemical Elivision methods and Western blot. Results： In 57 pulmonary carcinomas, the coincident results of caspase-3 and PARP proteins were observed by Western blot and immunohistochemistry, caspase-3and PARP proteins positive rates were 66.67%, 33.33% respectively. The positive expression of caspase-3 protein was highly associated with cellular differentiation degree （P=0.025）, lymph node metastasis（P=0.004） and the pathological types（P=0.036）. PARP expression was only associated with lymph node metastasis（P=0. 023）. In 57 pulmonary carcinomas, a negative correlation was present between caspase-3 and PARP protein expression （P = 0. 001）. Conclusion： Caspase-3 obviously inhibits invasion and metastasis of pulmonary carcinoma by extensively degrading target prc）teins such as PARP.

关 键 词：肺肿瘤 CASPASE-3 多聚ADP-核糖聚合酶 免疫组织化学 WESTERN BLOT 

分 类 号：R734.2[医药卫生—肿瘤]